Jane Street Group LLC Invests $68,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE)

Jane Street Group LLC bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 20,286 shares of the company’s stock, valued at approximately $68,000. Jane Street Group LLC owned about 0.14% of VYNE Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in shares of VYNE Therapeutics during the fourth quarter worth about $70,000. Adage Capital Partners GP L.L.C. acquired a new stake in VYNE Therapeutics in the 4th quarter worth approximately $516,000. Finally, Schonfeld Strategic Advisors LLC boosted its stake in VYNE Therapeutics by 4.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock worth $592,000 after purchasing an additional 8,058 shares in the last quarter. 83.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VYNE. HC Wainwright cut their price target on shares of VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating on the stock in a research note on Friday, April 25th. Wall Street Zen raised VYNE Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 30th.

VYNE Therapeutics Price Performance

VYNE Therapeutics stock opened at $1.00 on Monday. The stock has a 50-day moving average price of $1.38 and a 200 day moving average price of $2.16. The company has a market capitalization of $15.21 million, a price-to-earnings ratio of -1.16 and a beta of 1.56. VYNE Therapeutics Inc. has a 52 week low of $0.91 and a 52 week high of $4.30.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.09. The business had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.05 million. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 43.73%. Research analysts anticipate that VYNE Therapeutics Inc. will post -0.97 EPS for the current fiscal year.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.